Graft Versus Host Disease
Meeting Series
Meeting Series

Graft Versus Host Disease

Developments in Prevention, Treatment, and Patient Engagement

Not a member of My prIME? Join now for instant access.

Engage with top graft versus host disease (GVHD) experts and improve your knowledge with the most recent data on GVHD prevention and treatment strategies.

  • Increase treatment options for patients with acute and chronic GVHD
  • Maximize strategies for prevention and treatment of GVHD
  • Improve care giving with tactics for enhanced patient engagement


1.0 AMA PRA Category 1 Credit™



1.0 Contact Hour

Bring a GVHD expert-led, interactive meeting to your institution to elevate you and your colleagues’ knowledge on the newest strategies in prevention and treatment of acute and chronic GVHD.

5 min Introduction and Oncology Guru™ pre-assessment
10 min What’s known about the biology of GVHD
10 min Prophylactic, diagnostic, and prognostic developments in GVHD
20 min Targeted treatment developments in acute and chronic GVHD in 2017
5 min Patient and family education in GVHD
10 min Oncology Guru™ post-assessment, prIME Points™, conclusions, and questions


  • Corey Cutler, MD, MPH, FACP(C)Dana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Joyce Neumann, PhD, APRN, AOCN, BMTCNThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States


  • Corey Cutler, MD, MPH, FACP(C)Dana-Farber Cancer Institute
    Boston, Massachusetts, United States


  • Steven Devine, MDOhio State University
    Columbus, Ohio, United States
  • John DiPersio, MD, PhDWashington University School of Medicine in St Louis
    St Louis, Missouri, United States
  • David Miklos, MD, PhDStanford University
    Stanford, California, United States

This program is designed for physicians and registered nurses who comprise the core hematopoietic stem cell transplantation team, as well as community-based oncology physicians and nurses.

After successful completion of this educational activity, participants should be able to:

  • Explain the pathophysiology of acute GVHD, as well as the more recent understanding of the biology of chronic GVHD
  • Employ new approaches to GVHD prophylaxis when planning care for patients receiving allogeneic hematopoietic stem cell transplant (HSCT) and when providing patient and family education
  • Evaluate the potential clinical utility of data on diagnostic and prognostic markers of GVHD
  • Utilize treatment and management strategies incorporating new targeted therapies for acute and chronic GVHD based on an understanding of the mechanism of action, benefits, risks, dosing, monitoring, and management of the agents
  • Use shared decision making approaches to improve the quality of care for patients receiving allogeneic HSCT who may develop GVHD

This activity is supported by educational grants from Incyte, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Continuing Education

Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 1.0 contact hour may be earned for successful completion of this activity.


This activity is provided by the Annenberg Center for Health Sciences at Eisenhower.

Sunshine Act

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.